Kostka-Trabka E, Grodzińska L, Bieroń K, Basista M, Sławiński M, Kedzior A, Ochmański W
Zakładu Farmakologii Klinicznej Katedry Farmakologii, Instytutu Medycyny Wewnetrzne, AM, Krakowie.
Pol Tyg Lek. 1991;46(37-39):713-6.
Kallikrein (Padutin-Depot) was administered to 20 patients with obliterative atherosclerosis of the lower limbs of the II degree (19 patients) and IV degree (1 patient). The drug was given in the daily dose of 40 U i.m. for 28 days. An effect of kallikrein on the distance in intermittent claudication, rate of pain relieve after walking the maximal distance, blood flow in the lower limbs, and on the index of circulating aggregates have been determined. Clinical improvement has been noted after a 4-week therapy with kallikrein. The drug in a single dose of 40 U activates plasma fibrinolytic system for 5 hours and decreases the number of circulating aggregates (2-5 h). The authors explain kallikrein action as the release of endogenous bradykinin, which subsequently releases two epithelial mediators, i.e. PFG1 and EDRF.
将 Kallikrein（Padutin - Depot）用于治疗 20 例下肢闭塞性动脉粥样硬化患者，其中 II 度患者 19 例，IV 度患者 1 例。药物以每日 40 单位的剂量肌肉注射，持续 28 天。已测定 Kallikrein 对间歇性跛行距离、行走最大距离后疼痛缓解率、下肢血流量以及循环聚集指数的影响。使用 Kallikrein 进行 4 周治疗后观察到临床改善。单次 40 单位剂量的药物可激活血浆纤维蛋白溶解系统 5 小时，并减少循环聚集物数量（2 - 5 小时）。作者将 Kallikrein 的作用解释为内源性缓激肽的释放，随后缓激肽释放两种内皮介质，即 PFG1 和 EDRF。
